Eight numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
Metformin (OR 0.66; 95% CI 0.58-0.74; p < 0.05), Glucagon-like peptide-1 receptor agonist (GLP-1ra) (OR 0.73; 95% CI 0.59-0.91; p < 0.05), and sodium-dependent glucose transporters 2 inhibitor (SGLT 2i) (OR 0.77; 95% CI 0.69-0.87; p < 0.05) were associated with lower mortality risk, while insulin was associated with increased mortality risk (OR 1.40; 95% CI 1.26-1.55; p < 0.05).
What's more, metformin (OR 0.77; 95% CI 0.62-0.96; p < 0.05), GLP-1ra (OR 0.86; 95% CI 0.81-0.92; p < 0.05), and SGLT 2i (OR 0.87; 95% CI 0.79-0.97; p < 0.05) were also associated with a decreased risk of hospitalization, but insulin were associated with an increased risk of hospitalization (OR 1.31; 95% CI 1.12-1.52; p < 0.05).
← favours treatmentfavours comparator →
could be chanceAll-cause mortality
OR 0.660.58–0.74
Glycemic control
OR 0.730.59–0.91
Glycemic control
OR 0.770.69–0.87
All-cause mortality
OR 1.401.26–1.55
Adverse events & safety
OR 0.770.62–0.96
Adverse events & safety
OR 0.860.81–0.92
Adverse events & safety
OR 0.870.79–0.97
Adverse events & safety
OR 1.311.12–1.52
MetforminGlycemic controlAll-cause mortalityAdverse events & safety
1 / 3